Natera, Inc. (NASDAQ:NTRA) director and co-founder Jonathan Sheena has sold 3,340 shares of the company's common stock, according to a recent filing. The transaction, executed on November 6, 2026, carried a total value of $995,404, with share prices ranging from $304.24 to $325.53. The sale was conducted under a Rule 10b5-1 trading plan that Sheena adopted on December 12, 2025, a mechanism that allows company insiders to set up predetermined trading arrangements to sell shares at specified times.
Following the sale, Sheena directly holds 214,462 shares of Natera common stock. In addition, 8,250 shares are held indirectly by the Caraluna 1 Trust and another 8,250 shares by the Caraluna 2 Trust. Sheena disclaims beneficial ownership of the shares held by these trusts. All reported sales were executed pursuant to the Rule 10b5-1 trading plan.
The disclosure arrives as Natera's stock, currently trading at $312, has fallen more than 20% over the past week, reflecting the volatile price movements that have characterized the company's shares. Natera, valued at $45.2 billion, currently appears overvalued according to InvestingPro analysis, which places it among the platform's Most Overvalued stocks.
In other recent developments, Natera reported strong third-quarter 2026 earnings, with revenue increasing by 34% to $794 million compared to the previous year. The company's gross margin improved, supported by growth in its oncology and transplant sectors. Additionally, Natera raised its full-year revenue outlook to between $3.005 billion and $3.035 billion. Canaccord Genuity reiterated its Buy rating on Natera, highlighting the company's robust quarterly performance, particularly in the Signatera and Women's Health segments. Despite these positive earnings results, Natera's stock experienced a decline, indicating investor concerns about the company's near-term outlook and spending pace.
In leadership news, Natera announced a CEO transition from Steve Chapman to Solomon Moshkevich. Piper Sandler reiterated an Overweight rating on the company following this leadership change, maintaining a price target of $363.50. Natera also outlined a plan to achieve $6 billion in revenue by 2029.